Solpa-Sinus - Tablets 18 Pack


Earn 0 reward points

What are they for?

SolpaSinus tablets provide rapid relief of pain and nasal congestion and from the major cold and flu symptoms in a convenient easy to swallow tablet. Take at the first sign of nasal congestion when combined with

  • Blocked nose
  • Sore throat pain
  • Headache
  • Painful sinuses
  • Shivers
  • Fever

The medicine contains two active ingredients. Paracetamol is a painkiller and reduces your temperature when you have a fever. Pseudoephedrine hydrochloride is a decongestant which unblocks your nose and sinuses helping you breathe more easily without drowsiness.

How to take

  • Adolescents aged 12 to 18 years: One to two tablets up to three times daily as required.
  • Adults including the elderly: Two tablets up to three times daily as required.
  • Do not take more than 6 tablets in 24 hours.
  • Do not give to children under 12 years of age.

Do not exceed the stated dose


Active ingredients: Each tablet contains Paracetamol 500mg and Pseudoephedrine Hydrochloride 30mg. 

Other ingredients: Cellulose microcrystalline (E460), silica, colloidal anhydrous (E551), stearic acid (E570), magnesium stearate (E572), starch pregelatinised, povidone, crospovidone, croscarmellose sodium (E468), hypromellose (E464), macrogol, carnuba wax (E903), indigo carmine (E132).


  • Immediate medical advice should be sought in the event of an overdose, even if you feel well.
  • Contains Paracetamol. Do not take with any other paracetamol containing products.

Do not take

  • With any other flu, cold, decongestant or appetite suppressant products.
  • Everyday for more than 5 days,

Consult your doctor

  • Before taking this medicine, if you are under the care of your doctor or receiving prescribed medicines or are pregnant.
  • If symptoms persist consult your doctor
  • Prolonged use without medical supervision may be harmful.

Storage Instructions

  • Do not store above 25°C.
  • Keep out of the reach and sight of children.

See enclosed leaflet for further information